Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03078322 | AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression | PHASE2 | COMPLETED | 180 | — | — | Mar 5, 2018 | Oct 1, 2019 | Oct 9, 2019 | 22 | United States |
Depression questionnaire
| Arm | Type | Description |
|---|---|---|
| AV-101 | EXPERIMENTAL | L-4-chlorokynurenine 1440 mg daily for 14 days |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AV-101 | DRUG | Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant) |
| Placebo | DRUG | Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant) |
Inclusion Criteria: * Diagnosed with MDD, single or recurrent, and currently experiencing a MDE of at least 8 weeks in duration. * Has a history of inadequate response to at least 1 approved antidepressant including at least 1 and no more than 3 during the current depressive episode. * Meet the thr...